Daratumumab, an anti-CD38 monoclonal antibody shows promise in refractory autoimmune diseases such as systemic lupus erythematosus, Sjögren’s syndrome, and ANCA-associated vasculitis. This evidence concerns the gene CD38 and autoimmune disease.